Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Biochem Pharmacol

Retrieve available abstracts of 23 articles:
HTML format

Single Articles

    July 2021
  1. LU X, Yan G, Dawood M, Klauck SM, et al
    A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells.
    Biochem Pharmacol. 2021 Jul 12:114677. doi: 10.1016/j.bcp.2021.114677.
    PubMed     Abstract available

    June 2021
  2. KIM JH, Lee SJ, Kang KW, Lee BH, et al
    CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Biochem Pharmacol. 2021;190:114658.
    PubMed     Abstract available

    April 2021
  3. WANG F, Huang J, Guo T, Zheng Y, et al
    Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Biochem Pharmacol. 2021 Apr 5:114538. doi: 10.1016/j.bcp.2021.114538.
    PubMed     Abstract available

  4. CHIOU JT, Lee YC, Huang CH, Wang LJ, et al
    Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
    Biochem Pharmacol. 2021 Apr 5:114544. doi: 10.1016/j.bcp.2021.114544.
    PubMed     Abstract available

    January 2021
  5. MARENSI V, Keeshan KR, MacEwan DJ
    Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Biochem Pharmacol. 2021;183:114348.
    PubMed     Abstract available

    December 2020
  6. NABERGOJ S, Markovic T, Avsec D, Gobec M, et al
    EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
    Biochem Pharmacol. 2020 Dec 2:114352. doi: 10.1016/j.bcp.2020.114352.
    PubMed     Abstract available

  7. RODRIGUES MAD, Pimenta MV, Costa IM, Zenatti PP, et al
    Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase.
    Biochem Pharmacol. 2020;182:114230.
    PubMed     Abstract available

  8. VIGON L, Rodriguez-Mora S, Luna A, Sandonis V, et al
    Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.
    Biochem Pharmacol. 2020;182:114203.
    PubMed     Abstract available

    October 2020
  9. CARTER JL, Hege K, Kalpage HA, Edwards H, et al
    Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.
    Biochem Pharmacol. 2020 Oct 1:114253. doi: 10.1016/j.bcp.2020.114253.
    PubMed     Abstract available

    May 2020
  10. LEE YC, Wang LJ, Huang CH, Chiou JT, et al
    Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation.
    Biochem Pharmacol. 2020 May 21:114047. doi: 10.1016/j.bcp.2020.114047.
    PubMed     Abstract available

    April 2020
  11. GBYLI R, Song Y, Halene S
    Humanized mice as preclinical models for myeloid malignancies.
    Biochem Pharmacol. 2020;174:113794.
    PubMed     Abstract available

    November 2019
  12. LERNOUX M, Schnekenburger M, Dicato M, Diederich M, et al
    Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia.
    Biochem Pharmacol. 2019 Nov 7:113698. doi: 10.1016/j.bcp.2019.113698.
    PubMed     Abstract available

    September 2019
  13. FARAONI I, Giansanti M, Voso MT, Lo-Coco F, et al
    Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
    Biochem Pharmacol. 2019;167:133-148.
    PubMed     Abstract available

    June 2019
  14. QI W, Xu X, Wang M, Li X, et al
    Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis.
    Biochem Pharmacol. 2019;164:273-282.
    PubMed     Abstract available

    February 2019
  15. LIAO HC, Chou YJ, Lin CC, Liu SH, et al
    Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
    Biochem Pharmacol. 2019 Feb 26. pii: S0006-2952(19)30066.
    PubMed     Abstract available

    November 2018
  16. WANG LJ, Lee YC, Huang CH, Shi YJ, et al
    Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3/ROS/p38 MAPK/TTP axis-mediated TNF-alpha upregulation.
    Biochem Pharmacol. 2018 Nov 7. pii: S0006-2952(18)30472.
    PubMed     Abstract available

    August 2018
  17. BERMEJO M, Ambrosioni J, Bautista G, Climent N, et al
    Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.
    Biochem Pharmacol. 2018 Aug 21. pii: S0006-2952(18)30357.
    PubMed     Abstract available

    July 2018
  18. MARIOTTO E, Bortolozzi R, Volpin I, Carta D, et al
    EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells.
    Biochem Pharmacol. 2018;155:213-223.
    PubMed     Abstract available

    February 2018
  19. BORTOLOZZI R, Mattiuzzo E, Trentin L, Accordi B, et al
    Ribociclib, A Cdk4/Cdk6 Kinase Inhibitor, Enhances Glucocorticoid Sensitivity In B-Acute Lymphoblastic Leukemia (B-All).
    Biochem Pharmacol. 2018 Feb 3. pii: S0006-2952(18)30056.
    PubMed     Abstract available

  20. SU Y, Li X, Ma J, Zhao J, et al
    Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.
    Biochem Pharmacol. 2018;148:13-26.
    PubMed     Abstract available

    October 2017
  21. HAMDOUN S, Fleischer E, Klinger A, Efferth T, et al
    Lawsone derivatives target the Wnt/beta-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells.
    Biochem Pharmacol. 2017 Oct 20. pii: S0006-2952(17)30638.
    PubMed     Abstract available

    September 2017
  22. STEINHILBER D, Marschalek R
    How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
    Biochem Pharmacol. 2017 Sep 21. pii: S0006-2952(17)30603.
    PubMed     Abstract available

    June 2017
  23. PROBST L, Dachert J, Schenk B, Fulda S, et al
    Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death.
    Biochem Pharmacol. 2017 Jun 5. pii: S0006-2952(17)30435.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.